Trial record 5 of 173 for: "Gastrointestinal Stromal Tumors"
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: October 9, 2005
Last updated: April 29, 2012
Last verified: April 2012
This is a extension study of CSTI571B1201 study
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Novartis:
Primary Outcome Measures:
- To study the antineoplastic effect of the investigational drug.
Secondary Outcome Measures:
- To study the safety and pharmacokinetics of the investigational drug.
|Study Start Date:||September 2002|
|Primary Completion Date:||July 2005 (Final data collection date for primary outcome measure)|
Experimental: Imatinib Mesylate
400 mg once daily
Drug: Imatinib Mesylate
Other Name: STI571
Contacts and Locations